Publication

Oral formulations of fentanyl products and the benefit of their use in breakthrough cancer pain

Handsaker, Scott
; 
Dempsey, Laura
; 
Fabby, Carole
Thumbnail Image
Files
Thumbnail Image
fentanyl paper 06.03.18.pdf
Adobe PDF, 108.47 KB
Identifiers
http://hdl.handle.net/10379/7186
 https://doi.org/10.13025/22689
Publication Date
2015-04-22
Keywords
Oral formulations, Fentanyl, Cancer pain
Type
Article
Downloads
Show all metadata
Citation
Handsaker, Scott, Dempsey, Laura, & Fabby, Carole. (2015). Use of oral formulations of fentanyl for breakthrough cancer pain. International Journal of Palliative Nursing, 21(4), 168-172. doi: 10.12968/ijpn.2015.21.4.168
Abstract
Pain is one of the most common symptoms that palliative care teams face on a daily basis, affecting up to 70% of people with a malignancy (Soden et al, 2010) and significantly impacting on a patients quality of life (QoL) (Bornemann-Cimenti et al, 2013). Breakthrough cancer pain (BTCP) is identified as sudden in onset, self-limiting, severe in intensity, and with an average duration of 30 minutes (Handsaker et al, 2013; Bhatnagar, 2014). It is estimated to be prevalent in 40-80% of those with cancer pain (Handsaker et al, 2013).
Funder
Publisher
Mark Allen Group
Publisher DOI
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland
cbn
Collections
Nursing and Midwifery (Scholarly Articles)